168 related articles for article (PubMed ID: 28300891)
1. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
2. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
3. Lichen planopilaris-like eruption in chronic myeloid leukemia patient during treatment with nilotinib as second-line therapy.
Gardellini A; Guidotti F; Zancanella M; Maino E; Steffanoni S; Turrini M
J Oncol Pharm Pract; 2022 Jun; 28(4):969-971. PubMed ID: 35037787
[TBL] [Abstract][Full Text] [Related]
4. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
5. Unusual widespread cutaneous eruption due to nilotinib therapy for chronic myeloid leukemia.
Brazzelli V; Grasso V; Elena C; Orlandi E; Borroni G
G Ital Dermatol Venereol; 2015 Oct; 150(5):623-5. PubMed ID: 25014583
[No Abstract] [Full Text] [Related]
6. Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Patel AB; Solomon AR; Mauro MJ; Ehst BD
Dermatology; 2016; 232(1):122-5. PubMed ID: 26352467
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
8. A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
Hansen T; Little AJ; Miller JJ; Ioffreda MD
JAMA Dermatol; 2013 Mar; 149(3):330-2. PubMed ID: 23552567
[TBL] [Abstract][Full Text] [Related]
9. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
10. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
11. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.
Amitay-Laish I; Stemmer SM; Lacouture ME
Dermatol Ther; 2011; 24(4):386-95. PubMed ID: 21910796
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?
Francisco ARG; Alves D; David C; Guerra L; Pinto FJ; Almeida AG
Cardiovasc Toxicol; 2018 Oct; 18(5):431-435. PubMed ID: 29616409
[TBL] [Abstract][Full Text] [Related]
13. Skin and oral lesions associated to imatinib mesylate therapy.
Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
Durand MJ; Hader SN; Derayunan A; Zinkevich N; McIntosh JJ; Beyer AM
Microcirculation; 2020 Oct; 27(7):e12625. PubMed ID: 32395853
[TBL] [Abstract][Full Text] [Related]
15. Oral lichenoid reaction to imatinib (STI 571, Gleevec).
Lim DS; Muir J
Dermatology; 2002; 205(2):169-71. PubMed ID: 12218235
[TBL] [Abstract][Full Text] [Related]
16. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
Lai GM; Yan SL; Chang CS; Tsai CY
World J Gastroenterol; 2013 Feb; 19(8):1318-21. PubMed ID: 23483799
[TBL] [Abstract][Full Text] [Related]
18. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
20. [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].
Le Nouail P; Viseux V; Chaby G; Billet A; Denoeux JP; Lok C
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):686-8. PubMed ID: 17053739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
